Cargando…
Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
INTRODUCTION: The combination of lenvatinib plus pembrolizumab demonstrated a relevant clinical benefit in patients with endometrial carcinoma. The safety profile was consistent with the established profiles of each drug in monotherapy, with the most frequent adverse events being hypertension, an on...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535356/ https://www.ncbi.nlm.nih.gov/pubmed/36212444 http://dx.doi.org/10.3389/fonc.2022.979519 |